Cell line development, biologic and viral vector production, synthetic biology

Asimov is at the forefront of synthetic biology, offering an integrated platform that combines advanced genetic design with computational tools to facilitate the development of next-generation therapeutics. Their technology encompasses a comprehensive suite of engineered host cells, a vast library of validated genetic parts, and cloud-based design software. This platform enables the design, simulation, and optimization of genetic systems tailored to specific applications, such as biologics and gene therapies. Notably, Asimov's CHO Edge system achieves impressive production titers for protein therapeutics, while their LV Edge system streamlines lentiviral vector production, significantly reducing costs and supply chain risks associated with traditional multi-plasmid processes.

In addition to their core offerings, Asimov emphasizes the importance of data-driven models and machine learning in optimizing genetic engineering. Their approach includes multi-omics analysis for quality control and deeper biological insights, as well as AI tools that enhance the design and functionality of genetic constructs. By continuously refining their biological tools and processes, Asimov aims to democratize access to cutting-edge genetic design capabilities, thereby empowering biotech developers to create innovative therapies with greater efficiency and reliability.

United States

Asimov's mission is to advance humanity's ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform from cells to software to design and manufacture next-generation therapeutics, including cell & gene therapies, through a combination of products, services, & collaborations. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million.

Asimov

Company Details